Protea Biosciences Group, Inc. (OTCMKTS:PRGB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In connection with the provisions of the Restated Summit Loan Agreement, on October 26, 2017, Stephen Turner resigned as the Company’s Chief Executive Officer and Chairman of the Board. Mr. Turner will continue to serve as a consultant to the Company and shall receive compensation equal to up to 50% of his current base salary, together with all medical and related fringe benefits provided under his employment agreement with the Company that expires in April of 2018. There was no dispute or disagreement between Mr. Turner and the Company in relation to his resignation.
Item 9.01 Financial Statements and Exhibits
Protea Biosciences Group, Inc. ExhibitEX-3.1 2 tv477834_ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 PROMISSORY NOTE AND LOAN AGREEMENT Principal Amount: $2,…To view the full exhibit click here
About Protea Biosciences Group, Inc. (OTCMKTS:PRGB)
Protea Biosciences Group, Inc. is a molecular information company. The Company is engaged in developing and commercializing life science technologies, products and services to identify the molecules that are produced by living cells and all life forms. It also offers a platform technology, Laser Ablation Electrospray Ionization (LAESI), which enables the direct analysis, mapping and display of molecular information in living cells and tissue samples. The Company’s commercial development is centered in three business lines: Molecular Information Services, LAESI Instruments, Software and Consumables, and Molecular Diagnostics and Clinical Research. Its services enable the identification and quantitation of both small molecules (lipids and metabolites) and large molecules (proteins) and the services portfolio, inclusive of mass spectrometry imaging (MSI), proteomics, metabolomics, lipidomics and bioinformatics. Its clients include pharmaceutical, chemical and biotechnology companies.